<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10944596</article-id><article-id pub-id-type="pmc">2363511</article-id><article-id pub-id-type="pii">6691340</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1340</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Capecitabine in the treatment of metastatic renal cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Oevermann</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Buer</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hoffmann</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Franzke</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schrader</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Patzelt</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kirchner</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Atzpodien</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Haematology and Oncology, Medizinische Hochshule Hannover, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany</aff><aff id="aff2"><label>2</label>European Institute for Tumor Immunology and Prevention (EUTIP), Gotenstr. 152, Bonn, 53175, Germany</aff><aff id="aff3"><label>3</label>Robert Janker Cancer Center, Villenstr. 4, Bonn, 53129, Germany</aff><pub-date pub-type="epub"><day>16</day><month>08</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>09</month><year>2000</year></pub-date><volume>83</volume><issue>5</issue><fpage>583</fpage><lpage>587</lpage><history><date date-type="received"><day>09</day><month>06</month><year>1999</year></date><date date-type="rev-recd"><day>10</day><month>05</month><year>2000</year></date><date date-type="accepted"><day>17</day><month>05</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>To evaluate the therapeutic effects and systemic toxicities of a capecitabine-based home therapy regimen in patients with metastatic renal cell carcinoma, 30 patients were enrolled in a phase II clinical trial. Treatment consisted of oral capecitabine combined with subcutaneous recombinant human interferon-&#x003b1; 2a, recombinant human interleukin-2 and oral 13-cis-retinoic acid. There were two (7&#x00025;) complete responses (CRs) and eight (27&#x00025;) partial remissions (PRs), for an overall objective response rate of 34&#x00025; (95&#x00025; CI 17&#x02013;53&#x00025;). Except one, all responses are ongoing, with a median duration of 9+ and 8+ months for CRs and PRs, respectively. Additionally, 12 patients (40&#x00025;) reached stable disease. Eight patients (27&#x00025;) showed continued disease progression despite treatment. Therapy was well tolerated and was given in the outpatient setting. Capecitabine-related World Health Organization (WHO) grade 2 and 3 toxicities were observed in five and two patients respectively, and were limited to fatigue, nausea/vomiting, diarrhoea, stomatitis, dermatitis and hand-and-foot syndrome. The substitution of capecitabine for 5-FU in the pre-existing biochemotherapy regimen did not result in a reduced therapeutic efficacy and showed significant anti-tumour activity in patients with advanced renal cell carcinoma. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>renal cell carcinoma</kwd><kwd>capecitabine</kwd><kwd>13-cis-retinoic acid</kwd><kwd>alpha-interferon</kwd></kwd-group></article-meta></front></article>


